ArticleFrontiers in oncology2026
Cancer prevalence in the United States: trends and sociodemographic disparities based on national health interview survey data (2019-2023).
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer remains a leading cause of mortality in the United States. This study aimed to examine trends and disparities in the prevalence of selected cancers-any cancer, breast, cervical, prostate, and skin cancer-among U.S. adults from 2019 to 2023. Materials and methods: This cross-sectional study used data from the National Center for Health Statistics (NCHS) Interactive Summary Health Statistics for Adults. Cancer prevalence was based on self-reported physician diagnoses. Joinpoint regression analysis assessed temporal trends, with annual percentage change (APC) estimates and 95% confidence intervals (CI) reported. Analyses were stratified by year, gender, age, race/ethnicity, nativity, veteran status, employment status, geographic region, metropolitan statistical area (MSA), and Social Vulnerability Index (SVI). Results: The overall prevalence of any cancer remained stable from 2019 (9.6%, 95% CI: 9.3-9.9) to 2023 (9.8%, 95% CI: 9.5-10.1). However, notable disparities were observed. In 2023, White adults had the highest prevalence (11.7%, 95% CI: 11.3-12.2), while Asians had the lowest (3.5%, 95% CI: 2.6-4.8). Breast cancer prevalence in females rose slightly from 3.2% (95% CI: 2.9-3.5) in 2019 to 3.5% (95% CI: 3.2-3.8) in 2023, though not significantly. Cervical cancer in females significantly declined from 1.1% (95% CI: 0.9-1.3) to 0.9% (95% CI: 0.8-1.1) (APC: -6.05, 95% CI: -10.87 to -0.99). Prostate cancer in males rose slightly from 2.3% (95% CI: 2.1-2.6) to 2.5% (95% CI: 2.3-2.8), with Black males having the highest prevalence (3.6%, 95% CI: 2.7-4.7). Skin cancer in females significantly increased from 3.0% (95% CI: 2.7-3.3) to 3.3% (95% CI: 3.0-3.6) (APC: 2.25, 95% CI: 1.11 to 3.36), with the highest prevalence among White adults (4.7%, 95% CI: 4.4-5.0). Higher prevalence was generally observed among older adults, residents of non-MSA areas and the Midwest, individuals with low social vulnerability, the unemployed, U.S.-born individuals, and veterans. Conclusion: Although overall cancer prevalence remained relatively stable between 2019 and 2023, significant disparities persist across demographic, geographic, and socioeconomic groups. These findings emphasize the need for targeted cancer control strategies to address ongoing inequities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.